Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics società ha sostenuto
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions leggi di più
Overall, I think that my experience has been good, but we run full tilt, then stop, then full tilt, then stop. There is no constant. I wish the company would invest in the future and become a beginning to end pharm company instead of only thinking about clinical/commercial.
Quali sono alcune delle cose migliori della tuo team?
Overall, my team is easy to work with and friendly.
Che cosa sta andando male e come può essere migliorato?
There is nothing coming up behind our current compounds. We need some investment in the future or we will turn into a one and done company.
Che cosa deve fare il gruppo dirigente per migliorare?
We have no pipeline outside of compounds already known. We have very little science outside of the clinical arena. We have no ability or plan to do new med chem or look at other compounds that has been commumicated.
Other Employee Reviews for Karyopharm Therapeutics
×